Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 14/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.45 |
| ▸ | RBP4 | P02753 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12593540 | 0.89 | KMT2A (0.47) | SLC9A1CYP2C9CYP2C19CYP3A4KMT2A | |
| SCHEMBL1763520 | 0.89 | SLC9A1 (0.56) | SLC9A1CYP2C9CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL7994436 | 0.88 | SLC9A1 (0.51) | SLC9A1CYP2C9CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL1763883 | 0.87 | SLC9A1 (0.69) | SLC9A1CYP2C9CYP2C19CYP3A4RBP4 | |
| SCHEMBL1763661 | 0.85 | SLC9A1 (0.58) | SLC9A1CYP2C9CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL1763674 | 0.84 | NR3C1 (0.47) | SLC9A1CYP2C9CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL1763837 | 0.84 | SLC9A1 (0.50) | SLC9A1CYP2C9CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL1764148 | 0.84 | SLC9A1 (0.55) | SLC9A1CYP2C9CYP2C19CYP2D6KMT2A | |
| SCHEMBL1763461 | 0.84 | SLC9A1 (0.55) | SLC9A1CYP2C9CYP2C19CYP3A4KMT2A | |
| SCHEMBL1763080 | 0.83 | SLC9A1 (0.68) | SLC9A1CYP2C9CYP2C19CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118262-A1 | Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-19 | — | — | US | disclosed |
| US-20110118262-A1 | Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-19 | — | — | US | disclosed |
| US-20110118262-A1 | Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-19 | — | — | US | disclosed |
| WO-2010005783-A1 | PYRROLIDINYL AND PIPERIDINYL COMPOUNDS USEFUL AS NHE-1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118262-A1 | Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors | NHERF1, SLC9A1, SLC9A5 | SLC9A1 2/4885CYP2C9 1660/4885CYP2C19 917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.